专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明公开

EP0726903A1 MATRIX METALLOPROTEASE INHIBITORS-------------------------------- 有权
标题翻译：金属基蛋白酶抑制剂
公开(公告)号：EP0726903A1
公开(公告)日：1996-08-21
申请号：EP94932023.0
申请日：1994-11-03
申请人： SYNTEX (U.S.A.) INC.
发明人： CASTELHANO, Arlindo, L. , YUAN, Zhengyu , HORNE, Stephen , LIAK, Teng, J.
IPC分类号： C07D213 , A61K31 , A61P27 , A61P29 , A61P35 , A61P43 , C07C51 , C07C53 , C07C57 , C07C67 , C07C69 , C07C233 , C07C237 , C07C255 , C07C259 , C07C271 , C07C279 , C07C311 , C07C317 , C07C323 , C07C327 , C07D209 , C07D263 , C07D295 , C07F9
CPC分类号： C07D213/75 , C07C237/22 , C07C237/42 , C07C255/57 , C07C255/60 , C07C259/06 , C07C279/14 , C07C311/46 , C07C317/40 , C07C323/59 , C07C323/60 , C07C323/63 , C07C327/12 , C07C327/32 , C07C2601/14 , C07C2603/18 , C07D263/26 , C07D295/13 , C07F9/301 , C07F9/306 , C07F9/3211 , C07F9/3241 , C07F9/4816 , C07F9/582 , C07F9/60 , C07F9/65583

32. 发明公开

EP0696318A1 CATALYTIC ANTIBODIES WHICH HYDROLYZE PRIMARY AMIDES AND METHODS FOR ELICITING SUCH ANTIBODIES 失效
标题翻译：催化抗体;伯酰胺水解AND METHOD FOR显示此抗体
公开(公告)号：EP0696318A1
公开(公告)日：1996-02-14
申请号：EP94917894.0
申请日：1994-04-22
申请人： IGEN, INC. (a California corporation)
发明人： NAPPER, Andrew D. , TITMAS, Richard C. , MARTIN, Mark T. , HONG, Wonpyo
IPC分类号： A61K31 , A61K38 , A61K39 , A61P43 , C07D207 , C07F9 , C07K5 , C07K7 , C07K14 , C12N9
CPC分类号： C12N9/0002 , A61K38/00 , C07F9/3241 , C07F9/4816 , C07F9/5537 , C07K7/086 , C07K14/585 , C07K14/595
摘要： Described and claimed are compounds of formula (I) wherein Y is a polypeptide, R1 is bonded to the N-terminus of Y and is hydrogen or a branched or linear, substituted or unsubstituted, C1-21 alkyl, alkene, or alkyne group, R2 is a side chain of a naturally occurring amino acid, and X is (a), (b), (c). Such compounds are useful as haptens and immunogens for the elicitation of antibodies which catalytically enhance the rate of formation or hydrolysis of primary amide bonds. Also described and claimed are methods employing the compounds and antibodies.

33. 发明公开

EP0063896A1 Amino and substituted amino phosphinyl-alkanoyl compositions 有权
标题翻译：氨基和取代的氨基 - 膦基烷酰基制剂。
公开(公告)号：EP0063896A1
公开(公告)日：1982-11-03
申请号：EP82301923.7
申请日：1982-04-14
申请人： E.R. Squibb & Sons, Inc.
发明人： Petrillo, Edward W., Jr.
IPC分类号： C07F9/65 , A61K31/675
CPC分类号： C07F9/572 , C07D207/16 , C07D207/22 , C07F9/301 , C07F9/306 , C07F9/3211 , C07F9/3241 , C07F9/3288 , C07F9/52
摘要： Compounds of the formula
wherein X Is an imino acid or ester and R, is hydrogen.
are useful hypotensive agents due to their angiotensin converting enzyme inhibition activity.

34. 发明申请

US20140161839A1 AMINOPHOSPHINIC DERIVATIVES THAT CAN BE USED IN THE TREATMENT OF PAIN 审中-公开
标题翻译：可用于治疗疼痛的氨基磷酸衍生物
公开(公告)号：US20140161839A1
公开(公告)日：2014-06-12
申请号：US14182611
申请日：2014-02-18
申请人： PHARMALEADS
发明人： Bernard Roques , Herve Poras , Marie-Claude Fournie-Zaluski
IPC分类号： C07F9/30 , C07F9/32 , C07F9/6553 , A61K45/06 , A61K31/662 , A61K31/67 , A61K31/675 , A61K39/08 , C07F9/59
CPC分类号： C07F9/306 , A61K31/662 , A61K31/67 , A61K31/675 , A61K39/08 , A61K45/06 , C07F9/301 , C07F9/303 , C07F9/3211 , C07F9/3241 , C07F9/4816 , C07F9/59 , C07F9/655345
摘要： The present invention relates to a compound of the following general formula (I): R1—NH—CH(R2)—P(═O)(OR3)—CH2—C(R4)(R5)—CONH—CH(R6)—COOR7 (I) or a pharmaceutically acceptable salt of the latter, an isomer or a mixture of isomers in any proportions, especially a mixture of enantiomers, and in particular a racemic mixture, for which R1 represents a —C(═O)—O—C(R8)(R9)—OC(═O)—R10 group; R2 represents an optionally substituted hydrocarbon-based chain, an aryl or heteroaryl group or a methylene group substituted by a heterocycle; R3 represents a hydrogen atom or a —C(R12)(R13)—OC(═O)—R14 group; R4 and R5 form, together with the carbon that bears them, a saturated hydrocarbon-based ring or an optionally substituted piperidine ring or R4 represents a hydrogen atom and R5 represents a phenyl or a benzyl that is optionally substituted, a heteroaromatic ring or a methylene group substituted by a heterocycle; R6 represents an optionally substituted hydrocarbon-based chain or a phenyl or a benzyl that is optionally substituted; and R7 represents a hydrogen atom or a benzyl, alkyl, heteroaryl, alkylheteroaryl, —CHMe-COOR18, —CHR19—OC(═O)R20 and —CHR19—OC(═O)OR20 group. The present invention also relates to the use of these compounds as a medicinal product, and in particular for the treatment of pain, more advantageously neuropathic and neuroinflammatory pain, to their method of synthesis and also to the compositions containing them.
摘要翻译：本发明涉及以下通式（I）的化合物：R1-NH-CH（R2）-P（= O）（OR3）-CH2-C（R4）（R5）-CONH-CH（R6） -COOR7（I）或其后者的药学上可接受的盐，任何比例的异构体或异构体混合物，特别是对映异构体的混合物，特别是外消旋混合物，其中R1表示-C（= O） - O-C（R 8）（R 9）-OC（= O）-R 10基; R2表示任选取代的烃基链，芳基或杂芳基或被杂环取代的亚甲基; R3表示氢原子或-C（R12）（R13）-OC（= O）-R14基团; R4和R5与带有它们的碳一起形成饱和烃基环或任选取代的哌啶环，或R4表示氢原子，R 5表示任选取代的苯基或苄基，杂芳环或亚甲基被杂环取代的基团; R6表示任选取代的烃基链或任选取代的苯基或苄基; 并且R 7表示氢原子或苄基，烷基，杂芳基，烷基杂芳基，-CHMe-COOR 18，-CHR 19 -OC（= O）R 20和-CHR 19 -OC（= O）OR 20基团。本发明还涉及这些化合物作为药用产品的用途，特别是用于治疗其合成方法的疼痛，更有利的是神经性和神经炎性疼痛，以及含有它们的组合物。

35. 发明申请

US20110319366A1 Plasma Carboxypeptidase B Inhibitors 审中-公开
标题翻译：血浆羧肽酶B抑制剂
公开(公告)号：US20110319366A1
公开(公告)日：2011-12-29
申请号：US13220333
申请日：2011-08-29
申请人： Brad Buckman , Kumar Emayan , Imadul Islam , Karen May , Judi Bryant , Raju Mohan , Christopher West , Shendong Yuan
发明人： Brad Buckman , Kumar Emayan , Imadul Islam , Karen May , Judi Bryant , Raju Mohan , Christopher West , Shendong Yuan
IPC分类号： A61K31/662 , C07F9/40 , A61P7/02 , C07F9/30
CPC分类号： C07F9/655345 , C07C323/58 , C07C327/34 , C07D211/34 , C07F9/301 , C07F9/302 , C07F9/306 , C07F9/3211 , C07F9/3241 , C07F9/3882 , C07F9/4006 , C07F9/4056 , C07F9/4087 , C07F9/6524
摘要： Compounds of the following formula (I), for example: wherein R1, R2, R3, and R4 are described herein, are useful as inhibitors of plasma carboxypeptidase B. Pharmaceutical compositions containing these compounds, methods of using these compounds as antithrombotic agents and processes for synthesizing these compounds are also described herein.
摘要翻译：下列通式（I）的化合物，其中R1，R2，R3和R4如本文所述，可用作血浆羧肽酶B的抑制剂。含有这些化合物的药物组合物，使用这些化合物作为抗血栓形成剂和方法用于合成这些化合物也在本文中描述。

36. 发明授权

US07557143B2 Thyroid receptor ligands 失效
标题翻译：甲状腺受体配体
公开(公告)号：US07557143B2
公开(公告)日：2009-07-07
申请号：US10826100
申请日：2004-04-15
申请人： Denis E. Ryono , Jon J. Hangeland , Todd J. Friends , Tamara Dejneka , Pratik Devasthale , Yolanda V. Caringal , Minsheng Zhang , Arthur M. P. Doweyko , Johan Malm , Andrei Sanin
发明人： Denis E. Ryono , Jon J. Hangeland , Todd J. Friends , Tamara Dejneka , Pratik Devasthale , Yolanda V. Caringal , Minsheng Zhang , Arthur M. P. Doweyko , Johan Malm , Andrei Sanin
IPC分类号： A61K31/165 , A61K31/19 , C07C239/00 , C07C325/00 , C07C229/00 , C07C59/00
CPC分类号： C07C311/46 , A61K31/4439 , A61K31/662 , A61K45/06 , C07C43/29 , C07C43/295 , C07C59/68 , C07C59/72 , C07C65/24 , C07C65/26 , C07C69/16 , C07C69/736 , C07C69/94 , C07C205/38 , C07C217/58 , C07C233/29 , C07C235/34 , C07C235/42 , C07C235/46 , C07C235/52 , C07C235/60 , C07C235/62 , C07C235/64 , C07C311/37 , C07C2601/02 , C07C2601/14 , C07C2602/08 , C07C2603/18 , C07D213/30 , C07D239/26 , C07D257/04 , C07D263/14 , C07D263/32 , C07D277/24 , C07D285/06 , C07D307/42 , C07D307/52 , C07D307/87 , C07D317/58 , C07D317/60 , C07D333/32 , C07F9/306 , C07F9/3241 , C07F9/4056 , A61K2300/00
摘要： Thyroid receptor ligands are provided which have the general formula I wherein: R1 is R2 and R3 are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 5 carbons, provided that at least one of R2 and R3 is other than hydrogen; R4 is R5 and R6 are the same or different and are selected from hydrogen, aryl, heteroaryl, alkyl, cycloalkyl, aralkyl or heteroaralkyl. R7 is aryl, heteroaryl, alkyl, aralkyl, or heteroaralkyl; R8 is aryl, heteroaryl, or cycloalkyl; R9 is R7 or hydrogen; R10 is hydrogen, halogen, cyano or alkyl; R11 and R12 are each independently selected from the group consisting of hydrogen, halogen, alkoxy, hydroxy (—OH) cyano, and alkyl; R13 is carboxylic acid (COOH) or esters thereof, phosphonic and phosphinic acid or esters thereof, sulfonic acid, tetrazole, hydroxamic acid, thiazolidinedione, acylsulfonamide, or other carboxylic acid surrogates known in the art; R14 and R15 may be the same or different and are selected from hydrogen and alkyl, or R14 and R15 may be joined together forming a chain of 2 to 5 methylene groups [—(CH2)m-, m=2, 3, 4 or 5], thus forming 3- to 6-membered cycloalkyl rings; R16 is hydrogen or alkyl of 1 to 4 carbons; R17 and R18 are the same or different and selected from hydrogen, halogen and alkyl; n is 0 or an integer from 1 to 4; X is oxygen (—O—), sulfur (—S—), sulfonyl (—SO2—), sulfenyl (—SO—) selenium (—Se—), carbonyl (—CO—), amino (—NH—) or methylene (—CH2-); wherein the substituents are as described herein. In addition, a method is provided for preventing, inhibiting or treating diseases or disorders associated with metabolism dysfunction or which are dependent upon the expression of a T3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount.
摘要翻译：提供具有通式I的甲状腺受体配体，其中：R 1是R 2和R 3相同或不同，是氢，卤素，1至4个碳的烷基或3至5个碳原子的环烷基，条件是R2中的至少一个并且R 3不是氢; R 4是R 5和R 6相同或不同，并且选自氢，芳基，杂芳基，烷基，环烷基，芳烷基或杂芳烷基。 R7是芳基，杂芳基，烷基，芳烷基或杂芳烷基; R8是芳基，杂芳基或环烷基; R9为R7或氢; R 10是氢，卤素，氰基或烷基; R 11和R 12各自独立地选自氢，卤素，烷氧基，羟基（-OH）氰基和烷基; R13是羧酸（COOH）或其酯，膦酸和次膦酸或其酯，磺酸，四唑，异羟肟酸，噻唑烷二酮，酰基磺酰胺或本领域已知的其它羧酸替代物; R 14和R 15可以相同或不同，并且选自氢和烷基，或者R 14和R 15可以连接在一起形成2至5个亚甲基 - [ - （CH 2）m - ，m = 2,3,4或 5]，从而形成3-至6-元环烷基环; R16是氢或1至4个碳的烷基; R 17和R 18相同或不同，选自氢，卤素和烷基; n为0或1至4的整数; X是氧（-O-），硫（-S-），磺酰基（-SO 2 - ），亚磺酰基（-SO-），硒（-Se-），羰基（-CO-），氨基（-NH-）或亚甲基（-CH2-）; 其中取代基如本文所述。此外，提供了一种用于预防，抑制或治疗与代谢功能障碍相关或依赖于T3调节基因的表达的疾病或病症的方法，其中如上所述的化合物以治疗有效量施用。

37. 发明授权

US07528173B2 Plasma carboxypeptidase B inhibitors 失效
标题翻译：血浆羧肽酶B抑制剂
公开(公告)号：US07528173B2
公开(公告)日：2009-05-05
申请号：US10508169
申请日：2003-03-21
申请人： Brad Buckman , Kumar Emayan , Imadul Islam , Karen May , Judi Bryant , Raju Mohan , Christopher West , Shendong Yuan
发明人： Brad Buckman , Kumar Emayan , Imadul Islam , Karen May , Judi Bryant , Raju Mohan , Christopher West , Shendong Yuan
IPC分类号： A61K31/155 , C07C61/00
CPC分类号： C07F9/655345 , C07C323/58 , C07C327/34 , C07D211/34 , C07F9/301 , C07F9/302 , C07F9/306 , C07F9/3211 , C07F9/3241 , C07F9/3882 , C07F9/4006 , C07F9/4056 , C07F9/4087 , C07F9/6524
摘要： Compounds of the following formula (I), for example: (1), wherein R1, R2, R3, and R4 are described herein, are useful as inhibitors of plasma carboxypeptidase B. Pharmaceutical compositions containing these compounds, methods of using these compounds as antithrombotic agents and processes for synthesizing these compounds are also described herein.
摘要翻译：下述式（I）的化合物，例如：（1）其中R1，R2，R3和R4如本文所述，可用作血浆羧肽酶B的抑制剂。含有这些化合物的药物组合物，使用这些化合物的方法抗凝血剂和合成这些化合物的方法也在本文中描述。

38. 发明申请

US20050004184A1 Thyroid receptor ligands 失效
标题翻译：甲状腺受体配体
公开(公告)号：US20050004184A1
公开(公告)日：2005-01-06
申请号：US10826100
申请日：2004-04-15
申请人： Denis Ryono , Jon Hangeland , Todd Friends , Tamara Dejneka , Pratik Devasthale , Yolanda Caringal , Minsheng Zhang , Arthur Doweyko , Johan Malm , Andrei Sanin
发明人： Denis Ryono , Jon Hangeland , Todd Friends , Tamara Dejneka , Pratik Devasthale , Yolanda Caringal , Minsheng Zhang , Arthur Doweyko , Johan Malm , Andrei Sanin
IPC分类号： A61K20060101 , A61K31/16 , A61K31/165 , A61K31/19 , A61K31/277 , A61K31/421 , A61K31/44 , A61K47/00 , C07C205/00 , C07C235/20 , C07C255/49 , C07C381/00
CPC分类号： C07C311/46 , A61K31/4439 , A61K31/662 , A61K45/06 , C07C43/29 , C07C43/295 , C07C59/68 , C07C59/72 , C07C65/24 , C07C65/26 , C07C69/16 , C07C69/736 , C07C69/94 , C07C205/38 , C07C217/58 , C07C233/29 , C07C235/34 , C07C235/42 , C07C235/46 , C07C235/52 , C07C235/60 , C07C235/62 , C07C235/64 , C07C311/37 , C07C2601/02 , C07C2601/14 , C07C2602/08 , C07C2603/18 , C07D213/30 , C07D239/26 , C07D257/04 , C07D263/14 , C07D263/32 , C07D277/24 , C07D285/06 , C07D307/42 , C07D307/52 , C07D307/87 , C07D317/58 , C07D317/60 , C07D333/32 , C07F9/306 , C07F9/3241 , C07F9/4056 , A61K2300/00
摘要： Thyroid receptor ligands are provided which have the general formula I wherein: R1 is R2 and R3 are the same or different and are hydrogen, halogen, alkyl of 1 to 4 carbons or cycloalkyl of 3 to 5 carbons, provided that at least one of R2 and R3 is other than hydrogen; R4 is R5 and R6 are the same or different and are selected from hydrogen, aryl, heteroaryl, alkyl, cycloalkyl, aralkyl or heteroaralkyl. R7 is aryl, heteroaryl, alkyl, aralkyl, or heteroaralkyl; R8 is aryl, heteroaryl, or cycloalkyl; R9 is R7 or hydrogen; R10 is hydrogen, halogen, cyano or alkyl; R11 and R12 are each independently selected from the group consisting of hydrogen, halogen, alkoxy, hydroxy (—OH) cyano, and alkyl; R13 is carboxylic acid (COOH) or esters thereof, phosphonic and phosphinic acid or esters thereof, sulfonic acid, tetrazole, hydroxamic acid, thiazolidinedione, acylsulfonamide, or other carboxylic acid surrogates known in the art; R14 and R15 may be the same or different and are selected from hydrogen and alkyl, or R14 and R15 may be joined together forming a chain of 2 to 5 methylene groups [—(CH2)m-, m=2, 3, 4 or 5], thus forming 3- to 6-membered cycloalkyl rings; R16 is hydrogen or alkyl of 1 to 4 carbons; R17 and R18 are the same or different and selected from hydrogen, halogen and alkyl; n is 0 or an integer from 1 to 4; X is oxygen (—O—), sulfur (—S—), sulfonyl (—SO2—), sulfenyl (—SO—) selenium (—Se—), carbonyl (—CO—), amino (—NH—) or methylene (—CH2-); wherein the substituents are as described herein. In addition, a method is provided for preventing, inhibiting or treating diseases or disorders associated with metabolism dysfunction or which are dependent upon the expression of a T3 regulated gene, wherein a compound as described above is administered in a therapeutically effective amount.
摘要翻译：提供具有通式I的甲状腺受体配体，其中：R 1是R 2和R 3相同或不同，是氢，卤素，1至4个碳的烷基或3至5个碳原子的环烷基，条件是R2中的至少一个并且R 3不是氢; R 4是R 5和R 6相同或不同，并且选自氢，芳基，杂芳基，烷基，环烷基，芳烷基或杂芳烷基。 R7是芳基，杂芳基，烷基，芳烷基或杂芳烷基; R8是芳基，杂芳基或环烷基; R9为R7或氢; R 10是氢，卤素，氰基或烷基; R 11和R 12各自独立地选自氢，卤素，烷氧基，羟基（-OH）氰基和烷基; R13是羧酸（COOH）或其酯，膦酸和次膦酸或其酯，磺酸，四唑，异羟肟酸，噻唑烷二酮，酰基磺酰胺或本领域已知的其它羧酸替代物; R 14和R 15可以相同或不同，并且选自氢和烷基，或者R 14和R 15可以连接在一起形成2至5个亚甲基 - [ - （CH 2）m - ，m = 2,3,4或 5]，从而形成3-至6-元环烷基环; R16是氢或1至4个碳的烷基; R 17和R 18相同或不同，选自氢，卤素和烷基; n为0或1至4的整数; X是氧（-O-），硫（-S-），磺酰基（-SO 2 - ），亚磺酰基（-SO-）硒（-Se-），羰基（-CO-），氨基（-NH-）或亚甲基（-CH 2 - ）其中取代基如本文所述。此外，提供了一种用于预防，抑制或治疗与代谢功能障碍相关或依赖于T3调节基因的表达的疾病或病症的方法，其中如上所述的化合物以治疗有效量施用。

39. 发明申请

US20030212067A1 Matrix metalloprotease inhibitors 审中-公开
标题翻译：基质金属蛋白酶抑制剂
公开(公告)号：US20030212067A1
公开(公告)日：2003-11-13
申请号：US10418012
申请日：2003-04-16
发明人： Arlindo Lucas Castelhano , Steven Lee Bender , Judith Gail Deal , Stephen Horne , Teng J. Liak , Zhengyu Yuan
IPC分类号： A61K031/66 , A61K031/537 , A61K031/18
CPC分类号： C07D213/75 , C07C237/22 , C07C237/42 , C07C255/57 , C07C255/60 , C07C259/06 , C07C279/14 , C07C311/46 , C07C317/40 , C07C323/59 , C07C323/60 , C07C323/63 , C07C327/12 , C07C327/32 , C07C2601/14 , C07C2603/18 , C07D263/26 , C07D295/13 , C07F9/301 , C07F9/306 , C07F9/3211 , C07F9/3241 , C07F9/4816 , C07F9/58 , C07F9/60 , C07F9/65583
摘要： Compounds of the formula (I) 1 and their pharmaceutically acceptable salts inhibit matrix metalloproteases, such as stromelysin, gelatinase, matrilysin and collagenase, and are useful in the treatment of mammals having disease-states alleviated by the inhibition of such matrix metalloproteases.
摘要翻译：式（I）化合物及其药学上可接受的盐抑制基质金属蛋白酶，例如基质溶素，明胶酶，基质溶素和胶原酶，并且可用于治疗通过抑制这种基质金属蛋白酶而减轻疾病的哺乳动物。

40. 发明授权

US5670675A Retroviral protease inhibiting compounds 失效
标题翻译：逆转录病毒蛋白酶抑制化合物
公开(公告)号：US5670675A
公开(公告)日：1997-09-23
申请号：US409365
申请日：1995-03-23
申请人： Dale J. Kempf , Daniel W. Norbeck
发明人： Dale J. Kempf , Daniel W. Norbeck
IPC分类号： C07D295/18 , A61K31/00 , A61K31/10 , A61K31/12 , A61K31/135 , A61K31/15 , A61K31/165 , A61K31/195 , A61K31/335 , A61K31/40 , A61K31/415 , A61K31/425 , A61K31/44 , A61K31/445 , A61K31/47 , A61K31/495 , A61K31/535 , A61K31/54 , A61K38/00 , A61P31/12 , A61P37/04 , C07C31/125 , C07C33/18 , C07C33/26 , C07C33/46 , C07C39/12 , C07C43/164 , C07C43/174 , C07C43/205 , C07C43/215 , C07C43/23 , C07C43/30 , C07C43/313 , C07C43/315 , C07C45/00 , C07C45/29 , C07C45/56 , C07C45/59 , C07C45/62 , C07C45/67 , C07C45/74 , C07C49/04 , C07C49/12 , C07C49/17 , C07C49/175 , C07C49/20 , C07C49/215 , C07C49/233 , C07C49/24 , C07C49/255 , C07C53/134 , C07C69/34 , C07C69/65 , C07C69/732 , C07C211/27 , C07C215/06 , C07C215/18 , C07C215/20 , C07C215/28 , C07C217/04 , C07C225/06 , C07C229/08 , C07C229/26 , C07C229/34 , C07C233/35 , C07C233/36 , C07C233/40 , C07C233/78 , C07C235/10 , C07C235/12 , C07C235/34 , C07C235/78 , C07C237/04 , C07C237/10 , C07C237/20 , C07C237/22 , C07C239/08 , C07C239/10 , C07C239/18 , C07C239/20 , C07C247/10 , C07C251/40 , C07C271/20 , C07C271/22 , C07C271/34 , C07C275/00 , C07C275/16 , C07C275/24 , C07C311/03 , C07C311/05 , C07C311/06 , C07C311/13 , C07C311/18 , C07C317/10 , C07C317/28 , C07C317/44 , C07C323/11 , C07C323/12 , C07C323/25 , C07C323/41 , C07C323/60 , C07C381/00 , C07D207/06 , C07D207/08 , C07D207/12 , C07D207/16 , C07D207/24 , C07D209/42 , C07D211/22 , C07D211/54 , C07D211/62 , C07D211/96 , C07D213/30 , C07D213/40 , C07D213/42 , C07D213/55 , C07D213/56 , C07D213/70 , C07D213/81 , C07D213/82 , C07D215/16 , C07D217/14 , C07D217/16 , C07D217/26 , C07D231/10 , C07D233/60 , C07D233/61 , C07D233/84 , C07D239/38 , C07D263/06 , C07D263/32 , C07D277/24 , C07D277/28 , C07D277/36 , C07D277/42 , C07D277/56 , C07D279/12 , C07D295/088 , C07D295/14 , C07D295/15 , C07D295/155 , C07D295/185 , C07D295/20 , C07D295/205 , C07D295/215 , C07D295/22 , C07D295/26 , C07D303/04 , C07D303/22 , C07D303/36 , C07D303/48 , C07D305/14 , C07D307/42 , C07D317/12 , C07D413/12 , C07D417/12 , C07D487/04 , C07D521/00 , C07F7/02 , C07F9/30 , C07F9/32 , C07F9/53 , C07K5/02 , C07K5/06 , C07K5/062 , C07K5/078
CPC分类号： C07D207/08 , C07C211/27 , C07C215/18 , C07C215/20 , C07C215/28 , C07C229/08 , C07C229/26 , C07C229/34 , C07C233/36 , C07C233/40 , C07C235/10 , C07C235/12 , C07C235/34 , C07C235/78 , C07C237/10 , C07C237/20 , C07C237/22 , C07C239/10 , C07C239/18 , C07C239/20 , C07C247/10 , C07C251/40 , C07C271/20 , C07C271/22 , C07C271/34 , C07C275/16 , C07C275/24 , C07C311/03 , C07C311/13 , C07C311/18 , C07C317/10 , C07C317/28 , C07C317/44 , C07C323/12 , C07C323/25 , C07C33/46 , C07C381/00 , C07C43/164 , C07C43/1742 , C07C43/2055 , C07C43/215 , C07C43/23 , C07C43/30 , C07C43/315 , C07C45/004 , C07C45/29 , C07C45/567 , C07C45/59 , C07C45/62 , C07C45/673 , C07C45/74 , C07C53/134 , C07C69/34 , C07C69/65 , C07C69/732 , C07D207/24 , C07D209/42 , C07D211/62 , C07D213/30 , C07D213/40 , C07D213/42 , C07D213/56 , C07D213/70 , C07D213/81 , C07D213/82 , C07D215/16 , C07D217/16 , C07D217/26 , C07D231/12 , C07D233/56 , C07D233/84 , C07D239/38 , C07D249/08 , C07D263/32 , C07D277/24 , C07D277/28 , C07D277/36 , C07D277/42 , C07D277/56 , C07D295/088 , C07D295/15 , C07D295/155 , C07D295/185 , C07D295/205 , C07D295/215 , C07D295/26 , C07D303/04 , C07D303/22 , C07D303/36 , C07D303/48 , C07D307/42 , C07D317/12 , C07D413/12 , C07D417/12 , C07D487/04 , C07F9/3241 , C07F9/5333 , C07K5/021 , C07K5/06043 , C07K5/06052 , C07K5/06139 , A61K38/00 , C07C2101/14 , Y02P20/55
摘要： A retroviral protease inhibiting compound of the formula A-X-B or a pharmaceutically acceptable salt, prodrug or ester thereof, wherein X is a linking group; A is (1) substituted amino, (2) substituted carbonyl, (3) functionalized imino, (4) functionalized alkyl, (5) functionalized acyl, (6) functionalized heterocyclic or (7) functionalized (heterocyclic)alkyl; and B is (1) substituted carbonyl independently defined as herein, (2) substituted amino independently defined as herein, (3) functionalized imino independently defined as herein, (4) functionalized alkyl independently defined as herein, (5) functionalized acyl independently defined as herein, (6) functionalized heterocyclic independently defined as herein or (7) functionalized (heterocyclic)alkyl independently defined as herein.
摘要翻译：式A-X-B的逆转录病毒蛋白酶抑制化合物或其药学上可接受的盐，前药或酯，其中X为连接基团; A是（1）取代氨基，（2）取代羰基，（3）官能化亚氨基，（4）官能化烷基，（5）官能化酰基，（6）官能化杂环或（7）官能化（杂环）烷基; 并且B是（1）独立地定义如本文中的取代的羰基，（2）如本文独立定义的取代的氨基，（3）如本文独立定义的官能化亚氨基，（4）如本文独立定义的官能化烷基，（5）独立定义的官能化酰基如本文所述，（6）本文独立定义的官能化杂环或（7）如本文独立定义的官能化（杂环）烷基。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式